osteoporosis agents
Antiresorptives (bisphosphonates, denosumab, raloxifene) suppress osteoclasts; anabolics (teriparatide, romosozumab) build bone and must be followed by an antiresorptive. Oral bisphosphonates are first-line (avoid if CrCl <30–35). Denosumab works at any eGFR (watch severe hypocalcaemia in CKD) but causes rebound vertebral fractures if delayed or stopped without a bisphosphonate bridge.
- Thigh or groin pain on antiresorptives: obtain bilateral femur X-rays (lateral cortical thickening/beaking, transverse subtrochanteric line). If AFF confirmed → stop bisphosphonate, consult orthopaedics (IM nail), image contralateral femur, and consider teriparatide (not denosumab).
- Denosumab: never delay q6-month injections >1 month and never stop without transitioning to a bisphosphonate.
mechanism
- Bisphosphonates: bind hydroxyapatite and induce osteoclast apoptosis; persist in bone matrix for years (allowing drug holidays).
- Denosumab: human monoclonal antibody against RANKL → blocks osteoclast maturation/survival; fully reversible upon clearance.
- Teriparatide: recombinant PTH(1–34) given intermittently daily → net osteoblastic bone formation.
- Romosozumab: monoclonal antibody against sclerostin → dual effect (↑ bone formation + ↓ resorption).
- Raloxifene: SERM with oestrogen-agonist effect on bone and antagonist effect on breast/endometrium.
comparison and dosing
Ensure adequate calcium and vitamin D; correct hypocalcaemia before any antiresorptive and replete severe vitamin D deficiency before parenteral potent antiresorptives (denosumab or zoledronic acid, which carry high hypocalcaemia risk; oral bisphosphonates can be started alongside vitamin D repletion when serum calcium is normal).
| agent | osteoporosis dose | renal limit | major contraindications | key clinical notes |
|---|---|---|---|---|
| alendronate | 70 mg PO weekly (Paget: 40 mg/day × 6 mo) | CrCl <30–35 mL/min | oesophageal stricture/achalasia, inability to stay upright 30 min, hypocalcaemia | take fasting with plain water; upright & nothing by mouth 30–60 min; first-line |
| risedronate | 35 mg PO weekly or 150 mg monthly (Paget: 30 mg/day × 2 mo) | CrCl <30–35 mL/min | same as alendronate | delayed-release formulation can be taken immediately after breakfast |
| zoledronic acid | 5 mg IV annually (HCM: 4 mg IV; Paget: single 5 mg IV) | CrCl <35 mL/min | hypocalcaemia, CrCl <35 | flu-like acute-phase reaction (acetaminophen helps); consider dosing q18–24 mo after 3 y |
| denosumab | 60 mg SC q6 months (HCM: 120 mg SC) | no eGFR cut-off (extreme hypoCa risk in CKD 4–5/dialysis) | hypocalcaemia | reserve for bisphosphonate intolerance/contraindication; never stop without bisphosphonate bridge |
| teriparatide | 20 µg SC daily × max 24 months | CrCl <30 mL/min | Paget disease, skeletal radiation, bone malignancy/mets, hypercalcaemia, unexplained ↑ ALP | anabolic for very high risk or post-AFF; follow with antiresorptive |
| romosozumab | 210 mg SC monthly × 12 months | caution in severe CKD (hypoCa) | prior MI or stroke (CV boxed warning), hypocalcaemia | potent dual-action anabolic; follow with antiresorptive |
| raloxifene | 60 mg PO daily | none | VTE, CVD/stroke, premenopausal | vertebral fracture reduction only (no hip benefit); worsens hot flashes; ↓ ER+ breast cancer |
key points
- Drug holiday (bisphosphonates only): after 3–6 years of bisphosphonates, pausing therapy reduces AFF risk (risk drops sharply within 2 years of stopping) while residual skeletal bisphosphonate maintains partial protection. Never take a drug holiday from denosumab, raloxifene, or anabolics.
- Osteonecrosis of the jaw (ONJ): exposed jawbone persisting >8 weeks; rare at osteoporosis doses (far higher at monthly oncology IV dosing) — encourage routine dental hygiene; do not delay urgent fracture prevention for routine dental cleanings.
- Ontario: Oral bisphosphonates are general benefit. ODB Limited Use covers zoledronic acid (LU 436 postmenopausal OP, LU 523 male OP, LU 319 Paget), denosumab biosimilars (LU 687 postmenopausal, LU 688 male — high risk + failed/intolerant to oral bisphosphonate), and teriparatide (LU 635 / 676 — severe osteoporosis criteria).
adverse effects
- Oral bisphosphonates: oesophagitis/dyspepsia, musculoskeletal pain, rare AFF & ONJ.
- IV zoledronic acid: acute-phase fever/myalgias (24–72 h), nephrotoxicity if CrCl <35, hypocalcaemia, rare AFF & ONJ.
- Denosumab: severe prolonged hypocalcaemia (especially CKD 4–5 / vitamin D deficiency), cellulitis/dermatitis, rebound vertebral fractures on stopping, rare AFF & ONJ.
- Teriparatide: orthostatic hypotension, hypercalcaemia/hypercalciuria, nausea, leg cramps.
- Romosozumab: MI / stroke / CV death, hypocalcaemia, injection-site reactions, rare AFF & ONJ.
- Raloxifene: VTE, fatal stroke signal, hot flashes, leg cramps.
Prepared 2026-11-19. Not yet verified — check every number against the sources.